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ABSTRACT 
Cyclooxygenase (COX)-1, COX-2, and 
5-lipoxygenase (5-LOX) enzymes produce 
effectors of pain and inflammation in 
osteoarthritis (OA) and many other diseases. 
All three enzymes play a key role in the 
metabolism of arachidonic acid (AA) to 
inflammatory fatty acids, which contribute 
to the deterioration of cartilage. AA is 
derived from both phospholipase A2 (PLA2) 
conversion of cell membrane phospholipids 
and dietary consumption of omega-6 fatty 
acids.  Nonsteroidal  anti inflammatory 
drugs (NSAIDs) inhibit the COX enzymes, 
but show no anti-5-LOX activity to prevent the 
formation of leukotrienes (LTs). Cysteinyl LTs, 
such as LTC4, LTD4, LTE4, and leukoattractive 
LTB4 accumulate in several organs of mammals 
in response to NSAID consumption. Elevated 
5-LOX-mediated AA metabolism may 
contribute to the side-effect profile observed 
for NSAIDs in OA. Current therapeutics under 
development, so-called “dual inhibitors” of 
COX and 5-LOX, show improved side-effect 
profiles and may represent a new option in the 
management of OA.
Keywords: arachidonic acid; cyclooxygenase; 
f lavocoxid ;  leukotr ienes ;  l i cofe lone; 
5-l ipoxygenase; NSAIDs; prostacyclin; 
prostaglandin; tepoxalin; thromboxane
INTRODUCTION
Leukotrienes (LTs) play an important role 
in normal inflammatory processes. They 
are also intimately involved in allergic 
asthma, atopic dermatitis, allergic rhinitis, 
arthritis, atherosclerosis and ischemia, 
tumorigenesis, and septic shock [1-7]. LTs 
are leukoattractive substances as well as 
active modifiers of vascular dimension, fluid 
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balance, immunity, and pain responses. 
LTB4 is a potent chemoattactractive agent, 
which activates neutrophils at the site of injury 
by binding to cell receptors, inducing cell 
adhesion, neutrophil degranulation with release 
of degradative tissue enzymes, an increased 
production of cytokines, and pain induction [8]. 
Cysteinyl LTs induce vasoconstriction, mucus 
secretion, increased vascular permeability, and 
act in immunomodulation by binding specific 
receptors in smooth muscle and endothelial cells. 
Uncontrolled expression of LTs is instrumental 
in the pathogenesis of a wide variety of diseases 
affecting pulmonary, gastrointestinal (GI), 
cardiovascular (CV), and musculoskeletal 
function, including osteoarthritis (OA) [9].
Sánchez-Borges et al. [10] have suggested 
that,  second only to β- lactam drugs, 
nonsteroidal  ant i inf lammatory drugs  
(NSAIDs), as a class, are the leading cause 
of acute drug reactions and drug-induced 
side effects. Since 5-lipoxygenase (5-LOX) 
contributions to NSAID-induced adverse 
events are not widely recognized, it is 
important to understand these mechanisms 
and develop new types of antiinflammatory 
compounds that inhibit 5-LOX as well as 
the cyclooxygenase (COX) enzymes. This 
review presents available literature evidence 
published on Medline and PubMed between 
1980-2011 that supports the hypothesis that 
NSAID-induced 5-LOX upregulation of LT 
production from arachidonic acid (AA) may 
contribute to NSAID side effects, particularly 
those affecting the pulmonary, GI, CV, and 
renal systems. In addition, musculoskeletal 
effects of LTs, which occur after NSAID 
administration, will be described. Examples 
of current “dual inhibitors” of COX and 
5-LOX enzymes, both marketed and under 
development, are provided as they relate to 
reducing organ-specific adverse events.
METHODS
The authors independently reviewed the Medline 
and PubMed databases using the search words 
cyclooxygenase, COX-1, COX-2, lipoxygenase, 
5-LOX, nonsteroidal antiinflammatory 
drugs, NSAID toxicity, NSAID organ toxicity, 
arachidonic acid metabolism, and combinations 
thereof. Of more than 1000 scientific papers 
reviewed, the authors identified and summarized 
several hundred that were thought to be most 
relevant. These publications were then reviewed 
in detail and published papers selected as 
being most pertinent for the purposes of this 
review. This review is intended to present the 
current knowledge in peer-reviewed literature 
with regard to NSAID-induced increases in LTs 
through the 5-LOX enzyme, and is not intended 
as a systematic review.
AA METABOLISM
COX Enzyme Metabolism of AA
Although this review is not intended to 
compare the mechanisms of AA metabolism 
by the COX or 5-LOX enzymes in detail, it 
is important to understand basic fatty acid 
metabolism through these pathways. AA is 
an essential fatty acid obtained from the diet 
as well as from the enzymatic conversion of 
phospholipids from damaged cell membranes 
by phospholipase A2 (PLA2) [11]. This fatty 
acid is a necessary substrate for a variety 
of physiological processes, including those 
involving cell membrane composition, platelet 
function, inflammation, and tissue function 
and repair. During the metabolic conversion of 
AA by the COX enzymes, two oxygen molecules 
are added by a cyclooxygenase activity to 
AA to yield prostaglandin (PG)-G2 [12]. The 
PGG2 intermediate is then converted to PGH2
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by peroxidase activity via a reduction reaction. 
A variety of cellular and tissue specific 
isomerases and synthases then convert PGH2
to various PGs and prostacyclin (PC) as well as 
thromboxane (Tx). 
COX-1 is generally thought of as a 
housekeeping enzyme, maintaining low-level 
generation of fatty acid metabolites in various 
organs, while COX-2 is the inducible form of 
the enzyme [12]. It was originally hypothesized 
that differences in AA metabolism between 
COX-1 and COX-2 could be accounted for due 
to compartmentalization within the cell. Both 
enzymes, however, are associated with the 
endoplasmic reticulum and nuclear membranes 
in equal proportions [13]. The cyclooxygenase 
activity of COX-2 requires approximately 
10-fold less hydroperoxide for activation than 
that of COX-1, and metabolizes AA with a 
greater turnover rate [12]. It has also been 
shown that both COX-1 and COX-2 produce 
maintenance levels of PGI2, a vasodilator, 
from human endothelial cells [14]. PGI2 is, 
however, produced at a faster rate by COX-2 
with a threefold lower Km and 2.5-fold faster 
initial rate of velocity compared to COX-1 [15]. 
In addition, each isozyme appears to 
be coupled to specific synthases and/or 
isomerases for the final conversion of the 
PGH2 intermediate from each COX enzyme 
[11]. For example, PGI2 is specifically produced 
in the CV system through coupling of COX-2 
with PGI2 synthase, while TxA2 production 
is coupled in platelets to COX-1 and TxA2 
synthase. The importance of this coupling 
of the COX enzymes with specific synthases 
and isomerases led to the development of 
cyclooxygenase inhibitors with overlapping, 
yet specific side-effect profiles. The idealized 
conversion of phospholipids and dietary 
omega-6 fatty acids to AA and then to fatty 
acid metabolites is shown in Fig. 1.
Selective COX-2 inhibitors were conceived 
and designed to preserve PG production in the 
stomach and, thus, reduce the incidence of upper 
GI damage [16,17]. Six-month, well-controlled 
trials of celecoxib against traditional NSAIDs 
have shown this selective COX-2 inhibitor to 
be GI sparing [17,18]. In an analysis by the US 
Food and Drug Administration (FDA), however, 
follow-up of subjects in the Celecoxib Long-
term Arthritis Safety Study (CLASS) trial for 
an additional 6 months after the trial ended 
showed that when total ulcer complications 
were considered, according to the pre-specified 
criteria in the trial protocol, there was no 
appreciable difference in cumulative percentage 
between celecoxib and traditional NSAIDs 
[19,20]. Until longer, well-controlled, or phase 
4 studies are performed comparing celecoxib to 
traditional NSAIDs, there will be no definitive 
answer on this subject. Part of the reason for 
long-term ulcer complications with selective 
COX-2 NSAIDs may be that both COX-1 and 












Fig. 1. Metabolism of arachidonic acid by COX-1 and 
COX-2. COX=cyclooxygenase; PG=prostaglandin; 
PLA2=phospholipase A2; TXA2=thromboxane A2.
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COX-2 are required for maintenance of the 
gastric mucosa. GI toxicity of COX-2 agents is 
aggravated in the presence of even low-dose 
aspirin taken for cardioprotective purposes [21]. 
Therefore, PGs produced by both COX-1 and 
COX-2 contribute to the healing responses in 
the stomach. 
PGI2, generated from AA by COX enzymes 
in arterial endothelial cells, is required for 
vasodilatation of vessels and is antagonistic 
to vasoconstrictive TxA2 produced in platelets 
[22,23]. Selective COX-2 agents inhibit PGI2
generation while minimally affecting TxA2 in 
renal and cardiac microvasculature [24,25]. 
Such hemodynamic changes present clinically 
with reduced urine volume, hypertension, 
peripheral edema, myocardial ischemia, and 
may lead to acute CV events, such as myocardial 
infarction (MI) and stroke, particularly in 
susceptible individuals with pre-existing 
atherosclerotic disease. Immediately before MI, 
the level of vasodilatory PGs and PCs increases 
dramatically [26,27]. In animal models of MI, 
the concentrations of PGs and PCs were reduced 
when rats and mice were administered a selective 
COX-2 inhibitor compared with a placebo [28].
A meta-analysis of more than 4400 patients 
taking celecoxib for at least 6 weeks showed 
that there was an increase in MI over placebo, 
whereas there was no difference in composite 
analysis of CV deaths and strokes to placebo [29]. 
In addition, the same authors showed a 
significant increased risk of MI for celecoxib 
compared to placebo, diclofenac, ibuprofen, and 
paracetamol in a secondary meta-analysis of six 
studies (12,780 patients), but not other outcome 
measures. Although celecoxib appears not to 
elevate risk of overall CV dysfunction in normal 
patients compared to traditional NSAIDs, the 
data on rofecoxib are more compelling. Elevated 
CV adverse events, as shown in the Vioxx™
GI Outcomes Research (VIGOR) trial [16], 
inaccuracies in reporting that were discovered 
after publication of the trial for early MIs [30], 
and an excess of thrombotic events compared 
to placebo in the Adenoma Polyp Prevention 
in Vioxx™ (APPROVe) study [31] caused Merck 
to withdrawal rofecoxib from the market 
in September 2004 [32]. After this point, all 
NSAIDs carried the same CV warnings based 
on analysis of adverse events in the literature 
and in-market side effects. A recent review by 
Herman [33] summarized CV risk factors for 
naproxen, ibuprofen, and acetaminophen, with 
ibuprofen having the highest risk for adverse 
events. New findings from Danish nationwide 
registries of 83,677 patients with previous MIs 
found that even short-term exposure to NSAIDs 
substantially increased death/recurrent MIs [34].
PGs are potent renal vasodilators and, 
together with PCs, are required for proper renal 
perfusion and regulation of salt balance [35]. In 
the kidney, COX-2 is produced constitutively 
and upregulated in the presence of salt 
deprivation [36]. In the presence of reduced 
circulatory volume, increased production of 
vasoconstrictive compounds, such as Txs, 
supports blood flow by increasing blood 
pressure. In hypertensive individuals, selective 
COX-2 inhibitors were found to further increase 
systolic pressure [37,38]; thus, contributing to 
the increased incidence of acute CV events [39]. 
Chronic NSAID users (n=882) with hypertension 
or coronary artery disease compared to 
nonchronic NSAID users (n=21,694) analyzed 
from the INternational Verapamil Trandolapril 
STudy (INVEST) had an increased risk of CV 
adverse events during long-term follow-up [40]. 
Based on this analysis and many others, all 
NSAIDs appear to affect blood pressure to varying 
degrees. The dynamic process of AA metabolism 
and inhibition of specific fatty acid metabolites 
in the induction of NSAID-associated side 
effects may be further complicated by 5-LOX 
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pathway metabolite production in the presence 
of antiinflammatory agents.
5-LOX Metabolism of AA
LTs are normally produced by neutrophils, 
eo s inoph i l s ,  ba soph i l s ,  monocy te s , 
macrophages, mast cells, and B lymphocytes 
in response to trauma, infection, and/or 
inflammation. Lipid peroxidation of AA and 
linoleic acid results in the production of 
4-hydroxynonenal (4-HNE). The fatty acid-
derived 4-HNE, together with reactive oxygen 
species (ROS), act as a stimulus through 
mitogen-activated protein (MAP) kinase 
pathways to induce 5-lox gene expression 
primarily via nuclear factor-κB (NF-κB) 
and early growth response factor-1 (Egr-1) 
transcription factors (Fig. 2) [41]. The 5-lox
gene promoter and intronic sequences contain 
a number of inducible elements for binding of 
transcription factors, such as NF-κB, Sp1, Erg-1, 
Myb, and vitamin D3 [42]. A helper protein, 
5-LOX activating protein (FLAP), is coactivated 
and coexpressed with 5-LOX [43]. Lipid 
peroxidation, as a result of poor oxidative status, 
also destabilizes cell membranes, leading to 
induction of calcium-dependent PLA2 (cPLA2), 
which hydrolytically attacks phospholipids, 
leading to the generation of AA [44]. The 5-LOX 
enzyme translocates to the nuclear membrane 
and, along with FLAP, converts AA to LTs in a 
multistep process. AA, coordinated by FLAP, 
is converted by 5-LOX to the intermediate 
5-hydroperoxyeicosatetraenoic acid (HPETE) 
(Fig. 3). HPETE is converted to LTA4 by several 
NF-κB-dependent intermediate steps stimulated 
by cytokine-coupled ROS generation [45-47]. 
LTB4 and LTC4 are then formed from LTA4




















Fig. 2. Induction of 5-LOX and FLAP. AA=arachidonic acid; cPLA2=calcium-dependent phospholipase A2; Egr=early growth 
response factor; FLAP=5-LOX activating protein; HNE=hydroxynonenal; LOX=lipoxygenase; MAPK=mitogen-activated 
protein kinase; NFκB=nuclear factor-κB; ROS=reactive oxygen species.
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conversion by glutathione S-transferase, 
respectively. LTD4 is formed by liberation of 
glutaric acid from LTC4, and LTE4 by conversion 
of LTD4 by glutamyltranspeptidase and 
dipeptidase activity (Fig. 3). 
Other Pathways of AA Metabolism
Epoxygenase-derived eicosanoids are produced 
from AA by cytochrome P (CYP)-450 enzymes in 
response to vascular endothelial inflammation [48]. 
In particular, CYP2C and CYP2J family enzymes 
catalyze epoxidation of AA to epoxyeicosatrienoic 
acids [49]. Epoxyeicosatrienoic acids are then 
hydrolyzed to dihydroxyeicosatrienoic acids 
by soluble epoxide hydrolase and counteract 
vascular inflammation [50]. Mutations in 
CYP2J2 have been associated with elevated risk 
of CV dysfunction [51]. Alternatively, CYP4A 
and CYP4F family enzymes convert AA to 
20-hydroxyeicosatetraeonic acid, which is a 
potent vasoconstrictor that, when upregulated, 
contributes to oxidative stress and endothelial 
dysfunction in the CV system, and increases 
peripheral vascular resistance associated with 
some forms of hypertension [52]. AA is also 
metabolized by 12-LOX and 15-LOX to generate 
antiinflammatory lipoxins with and without 
the involvement of aspirin as a cofactor [53]. 
Although these enzymes represent alternate AA 
processing pathways and may produce molecules 
that counter or augment some of the effects of 
elevated LT generation and an overabundance of 
Txs in blood vessels, they are beyond the scope 




In patients with aspirin intolerance, nasal 
secretions contain increased levels of LTC4
and LTD4 during reactions to aspirin [54]. 
Aspirin-intolerant syndrome is characterized by 
urticaria, wheezing, bronchoconstriction, nasal 
polyps, and in severe instances, laryngeal edema 
and respiratory insufficiency [3]. Although 
there are several subtypes of aspirin sensitivity, 
these reactions have in common increased 
AA metabolism through the 5-LOX pathway, 
possibly due to blockage of the COX-1 synthase 
enzyme and reduction in available PGE2. As a 
consequence, an under-opposed increase in 
LT synthetase activity results in elevated tissue 
levels of bronchoconstrictive LTC4 and LTD4, 
histamine, and FLAP [55,56]. The incidence of 
aspirin-intolerant syndrome is about 10% of 
the US population, with most NSAIDs showing 
some level of cross-reactivity [57,58]. COX-2 
inhibitors also cross-react with aspirin with a 
much lower incidence and the order of cross-















Fig. 3. Metabolism of arachidonic acid by 5-LOX. 
FLAP=5-lipoxygenase activating protein;  
HPETE=hydroperoxyeicosatetraenoic; 
LOX=lipoxygenase; LT=leukotriene.
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strength and selectivity of COX-2 inhibition, eg, 
nimesulide > meloxicam > rofecoxib [59]. The 
data on celecoxib is mixed, with at least two 
small studies (n=27 and n=21) where tolerance 
was established by gradually increasing dose, 
showing no bronchospasms in asthmatic 
patients [60,61]. Another small study (n=59) 
and individual patient reports, however, show 
that celecoxib has a very low, but measurable, 
incidence of upper respiratory reaction in 
sensitive populations [62-64]. This suggests there 
is less cross-reactivity for more selective COX-2 
inhibitors with aspirin compared to traditional 
NSAIDs. Theoretically, antiinflammatory agents 
with 5-LOX inhibitory activity should be well-
tolerated by individuals with aspirin sensitivities 
despite inhibition of the COX enzymes.
Licofelone (also known as ML3000), a dual 
inhibitor of COX and 5-LOX currently in phase 3 
clinical trials in Europe, has been shown to 
mitigate the effects of antigen-induced asthma 
in a sheep model [65]. Another dual inhibiting 
therapeutic, flavocoxid, a medical food for 
the management of OA administered under 
physician supervision, a federal statutory 
requirement for this category in the US (Orphan 
Drug Act, 1988, 21 U.S.C. 360ee [b] [3]), 
exhibited significantly fewer upper respiratory 
adverse events in a clinical safety study when 
compared to placebo in OA subjects, possibly 
due to a reduction of LT expression as well as 
potential antiinfective properties [66].
GI
A number of factors contribute to GI ulceration, 
such as infection by Helicobacter pylori, 
production of ROS, and inflammatory responses, 
including LT generation [67]. Normally PGE2, 
produced by COX-1 in the gut, serves to protect 
the gastric mucosa by promoting mucous 
secretion and downregulating ROS production 
from neutrophils. Leukoattractive molecules 
promote neutrophil infiltration, which, in 
turn, results in high levels of ROS production 
in the mucosa and submucosa [67]. Although 
not chemoattractive to leukocytes, cysteinyl 
LTs cause vasoconstriction and ischemia, thus 
contributing to tissue damage [68]. Indomethacin 
and aspirin-induced gastric ulceration, for 
example, correlates with increased LT levels 
in the gastric mucosa of rats and pigs [69,70]. 
Administration of MK-886, a FLAP inhibitor, 
prior to indomethacin or aspirin treatment 
reduces the extent of gastric lesions in these 
animal models and reduces the indomethacin-
triggered production of LTB4. Even a relatively 
balanced COX enzyme inhibitor, such as 
nabumetone, which has a somewhat lower 
risk of GI side effects than other NSAIDs [71], 
increases metabolism of AA by 5-LOX. The 
nabumetone metabolite, 6-methoxy-2-
naphthylacetic acid, has COX inhibitory activity 
but also increases LTB4 levels in rat mucosa in 
vitro [72]. The 5-LOX inhibitor, phenidone, 
and the dual inhibitor of COX and 5-LOX, 
BW755C (3-amino-1-[trifluoromethylphenyl]-
2-pyrazoline hydrochloride), both suppress LTB4
production in rat mucosal tissue whilst in the 
presence of nabumetone in this model. 
Wallace and Ma [67] suggest that metabolic 
shunting toward the 5-LOX pathway is a major 
contributor to gastric injury in humans. When 
stimulated by calcium ionophore, human 
gastric mucosa and GI smooth muscle shows a 
reduction in the release of PGE2 and increases 
in production of LTB4 and cysteinyl LTs [73]. 
LT generation in this model is specifically reduced 
by the 5-LOX inhibitor, nordihydroguaiaretic 
acid (NDGA), and the COX/5-LOX dual inhibitor, 
BW755C. In human subjects, indomethacin 
(150 mg/day) produces endoscopically verified 
gastric damage that has been linked to LTB4-
mediated leukocyte adherence in blood vessels 
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of the gut [74]. In the same study, when subjects 
were coadministered indomethacin and a 
somatostatin analog that reduced leukocyte 
adherence, gastric lesions were ameliorated. 
Other studies also support the hypothesis that 
LTB4 attracts both eosinophils and neutrophils 
to the gastric mucosa endothelium when 
NSAIDs reduce PGE2, thereby causing damage to 
the submocosa [75-77]. In rheumatoid arthritis 
(RA) and OA subjects taking NSAIDs, a study 
showed statistically elevated levels of LTB4
and reduced PGE2 content in gastric biopsies 
compared with those taking placebo [78]. The 
evidence cited above suggests LT involvement 
in NSAID-induced GI toxicity.
Tepoxalin, a combined cyclooxygenase/
peroxidase inhibitor of COX-1, COX-2, and 
5-LOX, decreases LTB4 levels, neutrophil adhesion, 
gastric inflammation, and mucosal damage in 
rats, and is approved for use in canines for control 
of pain and inflammation associated with OA 
[79]. In human subjects, no ulcerations are found 
with doses of 200 or 400 mg twice daily (b.i.d.) 
of licofelone, whereas 500 mg of naproxen b.i.d. 
produces gastric lesions in 20% of subjects over a 
4-week period when assessed by endoscopy [80]. 
Flavocoxid (500 mg b.i.d.) showed statistically 
fewer upper GI adverse events compared 
to naproxen (500 mg b.i.d.) over a 12-week 
period [81]. Flavocoxid also had better overall 
tolerability in previously NSAID GI-intolerant 
patients over an 8-week administration and 
a reduction or cessation in gastroprotective 
medication use in these same patients [82].
CV
Mice with heterogeneous knockouts of 
the 5-lox gene maintained on high fat 
and cholesterol diets show a substantial 
decrease in atherosclerotic aortic lesions 
compared to a control wild-type strain [83]. 
5-LOX-expressing macrophages localize to 
aortic aneurysms and arterial lesions in both 
mice and humans [84,85], and mutations in the 
5-lox, LTA4 hydrolase, and arachidonate 5-LOX-
activating protein (ALOX5AP) genes, coding for 
FLAP, upregulate the production of LTB4 and 
are associated with an increased incidence of 
atherosclerosis, MI, and stroke in humans, 
especially in patients with high AA intakes 
due to poor diet [86-89]. Elevated serum LT 
concentrations occur in patients with acute 
CV events, suggesting involvement of 5-LOX-
mediated AA metabolism in CV disease [90].
In the VIGOR trial, rofecoxib showed a 
fourfold increase in CV-related events compared 
with naproxen [16]. Additionally, a retrospective 
study of over 54,000 patients in two different 
health plans showed a threefold increase in heart 
attack among elderly adults in the first 90 days of 
rofecoxib therapy of 25 mg or greater per day [91]. 
Similarly, in a retrospective cohort study of 
610,001 persons in a Medicaid population, 
acute MI, stroke, and death from coronary heart 
disease for patients taking celecoxib, rofecoxib, 
valdecoxib, ibuprofen, naproxen, diclofenac, 
and indomethacin were studied [92]. An 
increased risk of CV adverse events among all 
users of rofecoxib, valdecoxib, and indomethacin 
was found in patients with no CV disease. In 
patients with known CV disease, rofecoxib was 
associated with an increased risk of CV adverse 
events. The data on celecoxib is conflicting at 
doses higher than 200 mg per day. Two studies 
of celecoxib at ≥400 mg per day showed an 
increase the incidence of CV complications 
in a dose-dependent manner [93,94], whereas 
the Arthritis, Diet, and Activity Promotion 
Trial (ADAPT) showed no statistical increase 
in CV adverse events compared to placebo 
for celecoxib administered at 200 mg b.i.d. or 
400 mg daily [95]. All NSAIDs increase the risk 
of CV dysfunction, with naproxen recently 
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shown to be the safest in a large meta-analysis 
[96], though selective COX-2 agents are thought 
to elevate CV risks [97]. An association with an 
imbalance of COX-1 versus COX-2 activity that 
may reduce the concentration of vasodilatory 
PCs compared to vasoconstrictive Txs has been 
suggested as a possible cause for the elevated 
CV adverse event profile of these drugs [24]. 
Increased generation of vasoconstrictive 
cysteinyl LTs by 5-LOX while on NSAIDs may 
also play a role. 
A variety of cardiopulmonary complications 
highlight the interplay between the COX 
enzymes and the 5-LOX pathway [21,98]. 
Afferent vessel response in ischemic reperfusion 
is abolished by indomethacin in rats [99]. 
A specific 5-LOX inhibitor reverses this effect, 
presumably by suppressing LT production. 
Vasoconstriction observed in rings of human 
internal mammary arteries in organ baths 
exposed to angiotensin II is mediated by the 
action of TxA2 [100]. This activity, however, 
can be abated with a TxA2 agonist. In the same 
system, indomethacin caused an increase in 
angiotensin II-mediated vasoconstriction and 
LTC4 production. Specific 5-LOX inhibitors, 
such as phenidone and baicalein, prevented 
LTC4 generation in this same assay system 
[100]. Animals treated with celecoxib showed 
increased LT production in vascular tissue in the 
breast [101]. In humans with lung inflammation, 
200 mg per day of celecoxib elevated levels 
of LTE4 in urine [102]. Cultured human 
pulmonary artery endothelial cells exposed to 
calcium ionophore induce LT generation [103]. 
Hypoxic CV tissue from animals and humans 
demonstrates a similar leukocyte attraction 
mediated by LTB4, and vasoconstriction by LTC4
and LTD4 [104-106]. Licofelone and the dual 
COX/5-LOX inhibitors, CI-986 and BW-755C, 
counteracted the LT-mediated effects in these 
model systems. In rats with atherosclerotic 
lesions, licofelone reduces neo-intimal 
formation and decreases 5-LOX expression and 
LTB4 production in femoral arteries compared 
to rofecoxib [106]. Conversely, rofecoxib caused 
a nonstatistically significant increase in 5-LOX 
expression. Based on the evidence cited above, 
NSAIDs promote increased generation of LTs 
and could potentially exacerbate both known 
and undiagnosed CV disease through 5-LOX-
mediated LT generation.
Renal
Oxidative status and inflammation contribute to 
kidney disease, particularly during renal failure 
and hemodialysis [107]. Low polyunsaturated 
fatty acid intake correlates with the development 
of renal disease [108]. COX-1 and COX-2, as well 
as metabolites generated from polyunsaturated 
fatty acids by these enzymes, are important 
for renal function. In the kidney, COX-2 is 
produced constitutively [109]. Both PGs and PCs 
are required for proper renal perfusion and as 
key regulators of salt balance [35]. PGs, like PCs, 
are strong renal vasodilators, which maintain 
urine production by regulating renal blood flow. 
It has been found that macrophages present in 
the glomeruli synthesize LTB4 when exposed 
to calcium ionophore, suggesting that the 
5-LOX pathway is part of the normal regulatory 
capacity within the kidneys [110]. 5-LOX and 
FLAP are expressed at higher levels in humans 
with glomerulonephritis [111].
All NSAIDs have the capacity to cause renal 
damage. Under these circumstances, renal 
upregulation of 5-LOX expression and an 
increase in LTB4 generation causes influx of 
activated leukocytes that produce histamine, 
ROS, and cytokines [112-114]. Specific 
5-LOX inhibition of LTB4 and cysteinyl LT 
biosynthesis decreases LTC4 synthase activity 
and reduces renal impairment in experimental 
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glomerulonephritis [115,116]. Zileuton, a 5-LOX 
inhibitor, reduces the inflammatory effects of 
LTB4 in wild-type animals in this model [117]. 
In human clinical trials, although there was a 
lower incidence of hypertension with licofelone, 
there was no statistical difference between 
naproxen and licofelone in edema [118]. 
Tepoxalin did not affect renal function in 
canines [119,120]. Flavocoxid showed no 
statistically significant effect on markers 
of renal function in three different animal 
species [121-123] or in humans [82,121,124]. In a 
long-term, randomized, double-blind study there 
was a nonstatistically significant trend toward 
reduction in serum creatinine in the flavocoxid 
group compared with a similar trend toward an 
increase in creatinine in the naproxen group [81]. 
Further long-term studies of dual COX/5-LOX 
inhibitors are required to clarify their overall 
renal safety.
Musculoskeletal
The etiology of OA is complex and often 
initiated by injury or trauma. During subsequent 
development of the disease, metabolic and 
inflammatory factors contribute to cellular and 
cartilage degradation leading to the release of 
phospholipids from damaged cells, which are then 
converted by PLA2 into AA [125]. Other factors, 
such as a dietary imbalance between omega-6 and 
omega-3 fatty acid consumption, have also been 
implicated as a potential contributing factor to 
OA [126,127]. Treatment with NSAIDs also has 
the potential to aggravate cartilage damage by 
increasing intra-articular LT levels.
A greater induction of FLAP in cultured 
subchondral osteoblasts from patients with more 
severe OA was seen than from patients with 
moderate arthritis [128,129]. The combination 
of celecoxib and a 5-LOX inhibitor reduced 
the severity of collagen-induced cartilage 
damage in mice compared to celecoxib or the 
5-LOX inhibitor alone, suggesting the need for 
inhibition of both PG and LT production to 
prevent joint damage [130]. In a 1-year study, 
indomethacin decreased radiographically 
measured joint space in the knees of patients 
with OA compared to placebo [131]. One 
possible explanation for this result is induction 
of LT-coupled cytokine synthesis and LTB4
mRNA expression promoted by indomethacin, 
naproxen, and the COX-2 inhibitor, NS-398, a 
phenomenon demonstrated in cultured human 
articular chondrocytes and explants [132-134]. 
For these reasons, dual inhibitors may represent 
a therapeutic option to potentially preserve 
cartilage in OA [135,136].
In canines in which the anterior cruciate 
ligament is sectioned to induce OA, licofelone 
reduces gene expression of 5-lox, matrix 
metalloproteinases (MMPs), and several 
aggrecanases in synovial fluid [137]. Licofelone 
also reduces histological scores and synovial and 
vascular proliferation, as well as cartilage and 
bone destruction in rats [138]. Using this model, 
Boileau et al. [139] showed that licofelone 
reduces the chondrocyte apoptosis and the 
amount of aggrecanase, COX-2, and inducible 
nitric oxide synthase (iNOS) in the joint. Human 
and porcine synovial joint explants cultured for 
1-5 days and exposed to tepoxalin had lower 
cytokine expression than with other 5-LOX 
inhibitors, such as MK-886 [140]. Tepoxalin, an 
inhibitor of both COX and 5-LOX enzymes, also 
decreased the release of cartilage proteoglycans 
from canine cartilage explants exposed to 
interleukin (IL)-1β [141]. Finally, when subjects 
with symptomatic knee OA were treated with 
200 mg licofelone b.i.d. or 500 mg naproxen 
b.i.d. for 2 years in a double-blind, randomized 
clinical trial to evaluate treatment effects on 
cartilage loss measured by magnetic resonance 
imaging (MRI), the licofelone group showed 
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significantly less cartilage volume loss compared 
to the naproxen group [142]. This result suggests 
that dual inhibitors have the potential to 
preserve cartilage volume in patients with OA.
RA, a true inflammatory arthritis, is also 
treated with NSAIDs along with disease 
modifying agents, biologics, and other therapies. 
It has long been known that RA patients 
have elevated LT both systemically, excreted 
in urine, and in synovial fluid [143-145]. 
In RA, synovial fluid contains dramatically 
elevated numbers of leukocytes comprised 
predominantly of  neutrophils  [146] . 
Although the involvement of LT in RA is not 
completely understood, LT-deficient mice 
have been shown to be remarkably resistant to 
induction of inflammatory joint damage [147]. 
Significant elevations of LTB4 and LTC4
from neutrophils are also present in animal 
models that mimic RA, suggesting that the 
5-LOX pathway is significantly involved in 
generating inflammatory arthritis [148,149]. 
Neutrophils derived from RA patients treated 
with methotrexate show suppression of LTB4
synthesis in culture [150]. LTB4 has been shown 
in murine model of peritonitis to be involved in 
the amplification tumor necrosis factor (TNF)-α, 
IL-1β, and IL-18 to LTB4 as well [151]. Although 
these data are compelling, it remains to be 
seen whether LTs are a causative agent in the 
induction of RA.
Other Tissues
NSAID-induced LT generation also occurs 
in other tissues. Hypersensitivity to aspirin 
and other NSAIDs may produce urticaria and 
angioedema mediated by LTs, histamine, 
immunoglobulin (Ig)-E, and other inflammatory 
factors [152]. NSAIDs may also be etiologically 
associated with atopic dermatitis, especially in 
canines [153]. As with urticarial reactions [154], 
reduction of LT activity is essential for control of 
this condition. 
The lower digestive tract is particularly 
sensitive to the effects of antiinflammatory drugs, 
both from de novo-induced damage and from 
exacerbation of pre-existing inflammatory bowel 
diseases (IBD) [155]. IBDs are, in part, mediated 
by LTs [156]. NSAIDs aggravate these diseases 
by increasing production of ROS and LTs [157]. 
Although specific 5-LOX inhibitors, such as 
zileuton, have been used to treat conditions 
related to IBD [158], licofelone and tepoxalin 
have not been tested in these clinical settings. 
Flavonoids, like those in flavocoxid, reduce 
inflammation related to lower bowel diseases 
[159]. In an animal model of acute pancreatitis, 
flavocoxid reduces 5-LOX levels, blunts the 
induction of LTB4, reduces enzyme elevations, 
and preserves pancreatic histology [160].
COX/5-LOX “DUAL INHIBITORS” 
AND THEIR MECHANISMS OF 
ACTION
There are three COX/5-LOX dual inhibitors 
that are in the advanced stage of clinical 
development (licofelone) or on the market for 
OA as prescription therapeutics (tepoxalin and 
flavocoxid). Licofelone is a drug developed for 
humans, tepoxalin is approved for use in canines, 
and flavocoxid is a medical food indicated for OA 
in humans. Each of these agents has a distinct 
mechanism of action that may affect safety and 
efficacy. Licofelone strongly and specifically 
inhibits the cyclooxygenase moieties of the COX 
enzymes as well as 5-LOX induction [161].
The inhibition of LT generation by 
licofelone is due not to a direct interaction 
with 5-LOX, but rather to a modulation or 
interference with FLAP [162]. Licofelone has 
been shown to work by also downregulating 
specific inflammatory factors such as IL-1β, 
90 Adv Ther (2012)  29(2):79-98.
MMP-13, cathepsin K, and aggrecanases 
via modulation of p38 kinase [137,163]. 
Tepoxalin inhibits both cyclooxygenase and 
peroxidase moieties of the COX-1 and COX-2 
enzymes, as well as 5-LOX [164]. In addition, 
tepoxalin possesses an antioxidant activity, 
which inactivates NF-κB [165], the controlling 
factor for inducible inflammatory molecules 
such as cytokines, COX-2, 5-LOX, and iNOS. 
Flavocoxid, though similar to both licofelone 
and tepoxalin, is unique in its antiinflammatory 
mechanism of action. Flavocoxid modulates 
NF-κB activation in both macrophages and 
mice, decreasing expression of COX-2 and 
5-LOX [166,167]. In addition, flavocoxid 
upregulates I-κBα, the cytoplasmic control factor 
of NF-κB, thus, downregulating gene expression 
for multiple cytokines, including iNOS, COX-2, 
and 5-LOX [166-168]. Unlike licofelone and 
tepoxalin, however, flavocoxid shows balanced 
inhibition of the peroxidase moieties of COX-1 
and COX-2 enzymes, as well as having 5-LOX 
inhibitory activity [168]. Recent work employing 
oxygen-sensing cyclooxygenase  assays, however, 
has shown flavocoxid to have very limited 
cyclooxygenase moiety inhibition of COX-1 and 
no detectable cyclooxygenase inhibitory activity 
of COX-2 compared to indomethacin and 
NS-398, respectively [168]. In addition, flavocoxid 
has been shown to downregulate both p38 and 
JunK [166]. Finally, flavocoxid has potent, direct 
antioxidant activity and prevents the oxidative 
generation of malondialdehyde [166,168].
CONCLUSION
The history of NSAIDs for the treatment of OA, 
while replete with examples of symptomatic 
efficacy, has been tainted by organ-specific 
toxicities. These side effects tend to overlap for 
both classes of NSAIDs and vary somewhat from 
agent to agent. The in-market frequency and 
severity of some of these side effects in clinical 
trials has prompted “black box” warnings 
advising both physicians and patients about 
their potential risks on the GI tract and CV 
system. Two COX-2 inhibitors, rofecoxib and 
valdecoxib, were removed from the market, 
further contributing to an environment of 
confusion and caution regarding these agents. 
To date, clinicians have not fully appreciated the 
contributions of the 5-LOX pathway to NSAID-
linked side effects as a result of induction of LTs.
This article reviews the putative contributions 
of the 5-LOX pathway of AA metabolism in 
the exacerbation of NSAID-induced injury 
to multiple organ systems and suggests the 
pervasiveness of this phenomenon. Although 
the extent and complete role of LTs induced 
by COX-inhibiting NSAIDs in the production 
of organ toxicity is not fully defined, there are 
numerous examples of LT upregulation in cell 
and animal models as well as humans to suggest 
that these fatty acids may complicate therapy. 
Because inhibition of COX enzymes increases 
the conversion of AA by 5-LOX to leukoattractive 
and vasoconstrictive LTs, specific dual inhibitors 
of both COX and 5-LOX have been developed 
and are currently being prescribed to manage OA 
in humans and canines. These dual inhibitors, 
due to their inhibition of both COX and 5-LOX 
enzymes and other unique properties have, 
on balance, a superior adverse event profile in 
clinical trials and in-market experience. Further 
clinical studies and extended post-market 
surveillance are required to fully elucidate their 
safety and efficacy. 
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